Trial Search Results

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

To determine:

- Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer.

- Group A - subjects who have not previously received chemotherapy

- Group B - sujects who have received prior chemotherapy or could not tolerate chemotherapy.

- Clinical response will be determined by PSA and radiological response

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Infinity Pharmaceuticals, Inc.

Stanford Investigator(s):


  • Drug: IPI-504


Phase 2


Inclusion Criteria:

   - Adenocarcinoma of the prostate

   - Resolution of acute toxic side effects of prior chemotherapy

   - Castration resistant disease despite ongoing chemical or surgical castration

   - ECOG 0-1

   - PSA greater than or equal to 2

   - Group A -

      - No Prior treatment for prostate cancer with cytotoxic chemotherapy (neoadjuvant,
      adjuvant treatment permitted if more than 2 years out)

   - Group B

      - Radiographic evidence of metastatic disease

      - Prior tx with docetaxel-minimum of 2 cycles with progression by RECIST or PSA or
      intolerant of tx

      - Maximum of 3 prior chemotherapies

Exclusion Criteria:

   - Small cell carcinoma of the prostate

   - Treatment within 2 weeks with approved, investigational, or small molecule

   - Treatment within 4 weeks with biologic or external beam radiation

   - ANC <1,500 cells m3; Platelets <100,000 mm3; Hemoglobin <9.0g/dL

   - AST/ALT >2.5 ULN

   - Serum creatinine >3.0mg/dL

   - Active keratitis or keratoconjunctivitis

   - Previous treatment with 17-AAG, DMAG; or any other HSP-90 inhibitor

   - Baseline Qtc >450 mses

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting